MedTrace Logo

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

NCT02295475 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-09-28

No results posted yet for this study

Summary

This study is designed to compare the safety and effectiveness of two blood thinners, apixaban and warfarin, for the prevention of blood clots in patients who have a higher risk of blood clots than the general population, a condition called "antiphospholipid syndrome".

Conditions

Interventions

DRUG

Apixaban

DRUG

Warfarin

Sponsors & Collaborators

Principal Investigators

  • Scott C Woller, MD · Intermountain Health Care, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-10
Primary Completion
2020-04-30
Completion
2022-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02295475 on ClinicalTrials.gov